The Access to Medicine Foundation has published an independent analysis of the efforts made by pharma companies to address the issue of drug resistant infections.
Fighting
In the Antimicrobial Resistance Benchmark, it was revealed that GSK and Johnson & Johnson are leading the large research-based companies, with Mylan in front position out of the generics’ manufacturers and Entasis ahead of the other biotechs. However, the benchmark also noted that there is room for improvement in all those evaluated.